Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric RRMS phase 3 non-inferiority trial of ofatumumab and siponimod versus fingolimod
MOH_2021-12-27_010390Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Oct 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Ofatumumab arm, Siponimod arm and Fingolimod arm (3 arms). Started Oct 2021; status: recruiting.
02
Drugs
ofatumumabsiponimodfingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2021-12-27_010390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-27_010390.